Before the company applied to the FDA for the drug to be approved for obesity, Knudsen and her colleagues 'developed a new methodology to show how [GLP-1] drugs exert their effect on the brain by working on the circumventricular organs and communicating further into the hypothalamus, among other effects.' This was designed to illustrate how GLP-1 worked in 'well- defined neurons in the hypothalamus, in the hindbrain, and in the reward centers.' Their rationale for developing the method was because 'It was very important to show that these medicines work on defined brain circuits and not ones that may be related to psychiatric or cardiovascular side effects, for example' (Nair
For Drucker, now a senior scientist at Torontos Lunenfeld-Tanenbaum Research Institute and a Canadian Medical Hall of Famer, Ozempic (and other GLP-1 drugs) is no vanity project
The FDA prescribing information includes a boxed warning for risk of thyroid C-cell tumors and contraindication in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Packer, L.) 121126 (Academic Press, New York, New York, 1984)
it should not be red or pink